'200,000 → 1,180,000 → 600,000' Rollercoaster Stock Price... What Is Happening at Samchundang Pharmaceutical?
Questions Raised Over Generic License Agreements
Blogger Alleges Stock Manipulation and Front-Running
The stock price of Samchundang Pharmaceutical, which once ranked first in KOSDAQ market capitalization, has shown extreme volatility this year, repeatedly surging and plunging.
According to the Korea Exchange on April 5, the closing price of Samchundang Pharmaceutical at the end of last year was 232,500 won, but it soared to a record-high closing price of 1,184,000 won on March 30. This represents an increase of 409.2% compared to the beginning of the year. However, just three days later, on April 2, the stock closed at 609,000 won, down 18.15% from the previous trading day.
The starting point of the stock's sharp rise was a disclosure on March 19. After the company announced it had completed the submission of the Phase 1/2 clinical trial protocol (IND) for its oral insulin in Europe, Korea Investment & Securities released a report reflecting related expectations the following day, which rapidly improved investor sentiment. On that day, the stock price rose 14.1% to 907,000 won, and the market capitalization reached 21.2759 trillion won, surpassing Ecopro to take the top spot in KOSDAQ. The rally continued, and on March 25, the closing price of the stock exceeded 1 million won per share for the first time, earning it the title of "Emperor Stock."
In addition, news broke of a license agreement with a U.S. company for the generic versions of oral diabetes treatment Rybelsus and oral obesity treatment Wegovy Oral (semaglutide), pushing the stock up to 1,184,000 won on March 30.
However, the rally did not last long. The following day, the stock price plummeted to 829,000 won and continued to fall, only managing to rebound by over 6% on April 3.
In the market, doubts over the specifics of the generic license agreement are seen as the direct cause of the stock's sharp decline. Despite being a major contract worth about 15 trillion won, the partner company has not been disclosed, while the atypical profit-sharing structure and the relatively small initial milestone payment have fueled investor anxiety.
The controversy further intensified when, on the same day, a blogger raised suspicions of stock price manipulation. The blogger presented 12 allegations, including potential overstatement of performance and possible insider trading, questioning the background of the recent surge in the stock price.
To make matters worse, a notice of designation as an unfaithful disclosure entity was added to the mix. On March 31, the Korea Exchange gave notice of its intention to designate Samchundang Pharmaceutical as an unfaithful disclosure entity, and the following day, it was designated as a stock subject to short-selling restrictions due to excessive short selling.
The company immediately pushed back. Samchundang Pharmaceutical said, "This is not an issue with the entire performance, but a formal procedure by the exchange after news articles on profit forecasts for just one product, Eylea, out of over 200 products," adding, "The recent drop in the share price is not due to a loss in corporate value but rather to malicious rumors and artificial attacks from short sellers."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In addition, plans by the largest shareholder, CEO Jeon Inseok, to sell a large portion of his stake have also weighed on investor sentiment. CEO Jeon announced that from April 23 to May 22, he plans to dispose of 265,700 shares of Samchundang Pharmaceutical through after-hours block trading to secure funds for gift taxes and other tax payments. At the time of disclosure, the expected transaction amount was about 250 billion won.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.